The disease causes a progressive loss of central vision and it is the leading cause of blindness in developed countries. AMD has two forms; dry and wet. Wet AMD is currently treated with intravitreal antiangiogenic injections, but the dry form has no effective medical treatments. The number of people living with AMD is nearly 200 million worldwide and the annual direct health care cost from AMD is approximately €200 billion globally.
In summer 2018, we launched a Business Finland and Aalto University funded project aiming to develop and commercialize treatment for the eye disease, age-related macular degeneration (AMD). The technology can be applied to treat dry AMD and enable previously untreated patients to retain their vision. In addition, we believe that the treatment can prevent AMD from progressing to its quickly blinding exudative form (wet AMD).